Sarah Herterich

873 total citations
14 papers, 506 citations indexed

About

Sarah Herterich is a scholar working on Molecular Biology, Genetics and Organic Chemistry. According to data from OpenAlex, Sarah Herterich has authored 14 papers receiving a total of 506 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 4 papers in Genetics and 2 papers in Organic Chemistry. Recurrent topics in Sarah Herterich's work include DNA Repair Mechanisms (2 papers), Synthesis and Catalytic Reactions (2 papers) and Congenital heart defects research (2 papers). Sarah Herterich is often cited by papers focused on DNA Repair Mechanisms (2 papers), Synthesis and Catalytic Reactions (2 papers) and Congenital heart defects research (2 papers). Sarah Herterich collaborates with scholars based in Germany, United Kingdom and United States. Sarah Herterich's co-authors include Holger Hoehn, Helmut Hanenberg, Richard Friedl, Detlev Schindler, Andreas Reif, Ralf Dietrich, Christian Jacob, Bernd Gruhn, Klaus‐Peter Lesch and Alexander Strobel and has published in prestigious journals such as Cancer Research, Oncogene and British Journal of Cancer.

In The Last Decade

Sarah Herterich

13 papers receiving 480 citations

Peers

Countries citing papers authored by Sarah Herterich

Since Specialization

Citations

This map shows the geographic impact of Sarah Herterich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Herterich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Herterich more than expected).

Fields of papers citing papers by Sarah Herterich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Herterich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Herterich. The network helps show where Sarah Herterich may publish in the future.

Co-authorship network of co-authors of Sarah Herterich

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Herterich. A scholar is included among the top collaborators of Sarah Herterich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Herterich. Sarah Herterich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile 2025 ·Molecular Cancer Therapeutics ·Annette M. Vogl, (unknown), (unknown), (unknown), Sarah Herterich, (unknown), Philipp Cyprys, (unknown), Philipp Ochtrop, (unknown), (unknown), (unknown), (unknown), (unknown), Pamela A. Trail, Dominik Schumacher, (unknown), Björn Hock, Marc‐André Kasper, Jonas Helma	0
2	Abstract 2623: Enabling 5T4 for targeted cancer therapy: TUB-030, a novel ADC built with ethynylphosphonamidate conjugation chemistry, shows long-lasting anti-tumor activity via Topoisomerase-I inhibition with an optimized therapeutic index 2024 ·Cancer Research ·(unknown), (unknown), (unknown), Sarah Herterich, (unknown), Philipp Ochtrop, Philipp Cyprys, (unknown), (unknown), (unknown), (unknown), Pamela A. Trail, Dominik Schumacher, Marc‐André Kasper, Günter Fingerle‐Rowson, Björn Hock, (unknown), Annette M. Vogl	2
3	Abstract 2622: TUB-040, a novel Napi2b-targeting ADC built with ethynylphosphonamidate conjugation chemistry, demonstrates high and long-lasting anti-tumor efficacy via Topoisomerase-I inhibition and excellent tolerability predictive of a wide therapeutic window in humans 2024 ·Cancer Research ·(unknown), (unknown), (unknown), Sarah Herterich, (unknown), Philipp Ochtrop, Philipp Cyprys, (unknown), (unknown), (unknown), (unknown), Pamela A. Trail, Dominik Schumacher, Marc‐André Kasper, Günter Fingerle‐Rowson, Björn Hock, (unknown), Annette M. Vogl	3
4	Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates 2023 ·Molecular Cancer Therapeutics ·(unknown), (unknown), (unknown), Sarah Herterich, (unknown), Philipp Cyprys, (unknown), Philipp Ochtrop, Christian P. R. Hackenberger, Dominik Schumacher, Jonas Helma, Annette M. Vogl, Marc‐André Kasper	8
5	Dual Role of Dysfunctional Asc-1 Transporter in Distinct Human Pathologies, Human Startle Disease, and Developmental Delay 2023 ·eNeuro ·(unknown), (unknown), Natascha Schaefer, Vikram Babu Kasaragod, Sarah Herterich, (unknown), Victoria L. Harvey, Carmen Villmann	5
6	Enzyme autoinduction by mitotane supported by population pharmacokinetic modeling in a large cohort of adrenocortical carcinoma patients 2018 ·European Journal of Endocrinology ·(unknown), Max Taubert, Max Kurlbaum, Sebastian Frechen, Sarah Herterich, Felix Megerle, Stefanie Hamacher, Martin Faßnacht, Uwe Fuhr, Matthias Kroiß	13
7	Nuclear import of LASP-1 is regulated by phosphorylation and dynamic protein–protein interactions 2012 ·Oncogene ·(unknown), Cora Reiß, (unknown), Sarah Herterich, (unknown), Joachim Kremerskothen, Hermann Pavenstädt, Urs Lewandrowski, Albert Sickmann, Elke Butt	49
8	LOH and copy neutral LOH (cnLOH) act as alternative mechanism in sporadic colorectal cancers with chromosomal and microsatellite instability 2011 ·Carcinogenesis ·R Melcher, Elena Hartmann, (unknown), Sarah Herterich, (unknown), Lil‐Sofie Ording Müller, Elen Rosler, Theodor Kudlich, Oliver Al‐Taie, Andreas Rosenwald, Tiemo Katzenberger, (unknown), Stefan Seibold, Dorothee Rogoll, (unknown), M Scheurlen, (unknown)	32
9	Nuclear localisation of LASP-1 correlates with poor long-term survival in female breast cancer 2010 ·British Journal of Cancer ·(unknown), Thomas G. P. Grünewald, (unknown), Ulrike Kämmerer, Sarah Herterich, M Kapp, A Hönig, Elke Butt	54
10	P.1.a.017 Effect of a functional NOS1 promoter polymorphism and life events on personality, anxiety and depressiveness 2010 ·European Neuropsychopharmacology ·Jaanus Harro, (unknown), Andreas Reif, Evelyn Kiive, Sarah Herterich, Tiia Tulviste, Toomas Veidebaum, Klaus‐Peter Lesch	2
11	FZD3 is not a risk gene for schizophrenia: a case-control study in a Caucasian sample 2007 ·PubMed ·Andreas Reif, Martin Melchers, Alexander Strobel, Christian Jacob, Sarah Herterich, Klaus‐Peter Lesch, Mariusz Zimmer	6
12	Disruption of the FA/BRCA pathway in bladder cancer 2007 ·Cytogenetic and Genome Research ·Kornelia Neveling, Reinhard Kalb, Andrea R. Florl, Sarah Herterich, Richard Friedl, Holger Hoehn, Christiane Hader, (unknown), I. Nanda, Claus Steinlein, M. Schmid, H. Tönnies, Carolyn D. Hurst, Margaret A. Knowles, Helmut Hanenberg, Wolfgang A. Schulz, Detlev Schindler	32
13	A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function 2006 ·Molecular Psychiatry ·Andreas Reif, Sarah Herterich, Alexander Strobel, Ann‐Christine Ehlis, Dieter Saur, Christian Jacob, T. F. Wienker, (unknown), Sabrina Fritzen, Ulrich Walter, Angelika Schmitt, Andreas J. Fallgatter, Klaus‐Peter Lesch	172
14	Reverse mosaicism in Fanconi anemia: natural gene therapy via molecular self-correction 2002 ·Cytogenetic and Genome Research ·(unknown), Helmut Hanenberg, Stephan Lobitz, Richard Friedl, Sarah Herterich, Ralf Dietrich, Bernd Gruhn, Detlev Schindler, Holger Hoehn	128

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact